Stock of the Day

Veeva Systems (VEEV)

$313.01

+$15.66 (+5.3%)

Market Cap: $48.14B

About Veeva Systems

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.

The company also provides Veeva Development Cloud, a suite of applications for the clinical, regulatory, quality, and safety functions, including Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality; Veeva QualityOne, a quality and document management, and training solution; Veeva RegulatoryOne, a solution that helps companies to manage regulatory submission content; and Veeva Claims addresses the end-to-end product and marketing claims management process. In addition, it offers professional and support services, including implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; data migration and systems integrations technical consulting services; training on its solutions; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

Veeva Systems Bull Case

Here are some ways that investors could benefit from investing in Veeva Systems Inc.:

• Veeva Systems Inc. recently expanded its partnership with IQVIA, which selected Veeva's Clinical Trial Management System, electronic Trial Master File, Study Startup, and Site Connect products as enterprise standards across its global research operations. This strategic move deepens Veeva's role in clinical execution workflows and broadens its reach across contract research and biopharma customers, potentially increasing recurring revenue and customer retention.
• The company reported strong third-quarter earnings, beating analysts' consensus estimates with $2.35 in earnings per share compared to the expected $2.23. Revenue also exceeded expectations at $927.96 million, up 17.6% year-over-year, demonstrating robust demand for its cloud-based software solutions in the life sciences industry.
• Veeva Systems Inc. has set aggressive guidance for fiscal year 2027, projecting earnings per share of $9.21 and revenue of $3.7 billion. This guidance significantly exceeds the consensus estimates of $8.58 for EPS and $3.6 billion for revenue, indicating management's confidence in continued growth and operational efficiency.
• The stock is currently trading at $313.01, near its 52-week high of $315.02, reflecting strong investor sentiment and technical momentum. This price level suggests that the market is valuing the company's growth trajectory and market position highly, with institutional investors showing increased interest in the stock.
• Veeva's Veeva Basics suite is gaining traction with more than 175 emerging biotechnology companies, supporting the company's strategy of building early relationships that may develop into larger, long-term customers as these firms advance their drug pipelines. This broadening adoption among early-stage biotechs could unlock long-term revenue opportunities.

Veeva Systems Bear Case

Investors should be bearish about investing in Veeva Systems Inc. for these reasons:

• The company's price-to-earnings ratio stands at 48.04, which is relatively high compared to many other software companies. This valuation may leave little room for error if growth slows or if the company fails to meet its aggressive earnings guidance, potentially leading to a significant stock price correction.
• Insider selling has been notable, with executives such as Daniel J. Rizzo and Thomas D. Schwenger selling significant portions of their holdings in recent months. For example, Rizzo sold 4,841 shares in October, and Schwenger sold 10,000 shares in August, which could signal a lack of confidence in the stock's near-term upside or simply reflect personal financial planning.
• Some institutional investors have reduced their stakes in Veeva Systems Inc. For instance, Curated Wealth Partners LLC cut its stake by 45.6% during the third quarter, and Seilern Investment Management Ltd sold 138,217 shares. These moves could indicate that some large investors are taking profits or reassessing their positions in the stock.
• The company's research and development spending is expected to decelerate, as noted by Oppenheimer, which could impact its ability to innovate and maintain its competitive edge in the rapidly evolving life sciences technology sector. This deceleration may be a concern for investors who prioritize ongoing innovation and product development.
• Veeva Systems Inc. does not pay a dividend, with a dividend yield of 0.00%. This may be a drawback for income-focused investors who prefer stocks that provide regular cash flows, especially in a market where dividend-paying stocks are often favored for their stability and income potential.

Recent News

• Veeva Systems Climbs 5% to $312, Adding $2.4 Billion in Market Value (247wallst.com)
• Veeva Systems' Research and Development Growth Tracking to Plan, Oppenheimer Says (finance.yahoo.com)
• Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know (finance.yahoo.com)
• Is Veeva (VEEV) a Buy as Wall Street Analysts Look Optimistic? (finance.yahoo.com)
• Veeva Stock Breaks Out As Big Money Grabs Exposure To The AI Software Play (finance.yahoo.com)
• Veeva Systems (VEEV) Becomes Default Clinical Software Across A Major Research Partner (finance.yahoo.com)
• Is Veeva Systems (VEEV) Quietly Redefining Clinical Tech Moats With IQVIA Deal And Basics Uptake? (finance.yahoo.com)
• Veeva to Host Virtual Investor Day on November 5, 2026 (prnewswire.com)
• Global Life Sciences IT Market Opportunities and Strategies to 2035 | Capitalize on AI, Cloud and Bioinformatics as IQVIA, Oracle, Accenture, Veeva Systems and SAP Target $82.24B (finance.yahoo.com)
• Veeva Systems (VEEV) Stock Trades Up, Here Is Why (finance.yahoo.com)